Evidence map›Paper›PMID 37250868›Full record

ReviewJournal of clinical and experimental hepatology

INASL-SAASL Consensus Statements on NAFLD Name Change to MAFLD.

Shivaram P Singh, Ajay Duseja, Mamun Al Mahtab, Prajna Anirvan, Subrat K Acharya, Sheikh Mohammad Fazle Akbar, Amna S Butt, Anuradha Dassanayake, Arka De, G P Dhakal and 11 more

Abstract readReview
In one paragraph

Review in Journal of clinical and experimental hepatology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Shivaram P SinghKalinga Gastroenterology Foundation, Cuttack 753001, Odisha, India.
Ajay DusejaDepartment of Hepatology, Postgraduate Institute of Medical Education and Research, Chandigarh 160012, India.
Mamun Al MahtabDepartment of Interventional Hepatology, Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh.
Prajna AnirvanKalinga Gastroenterology Foundation, Cuttack 753001, Odisha, India.
Subrat K AcharyaDepartment of Gastroenterology and Hepatology, KIIT University, Patia, Bhubaneshwar 751024, Odisha, India.
Sheikh Mohammad Fazle AkbarDepartment of Gastroenterology and Metabology, Ehime University Graduate School of Medicine, Toon, Ehime, Japan.
Amna S ButtSection of Gastroenterology, Department of Medicine, The Aga Khan University Hospital, Karachi, Sindh, Pakistan.
Anuradha DassanayakeColombo North Centre for Liver Disease, Faculty of Medicine/University of Kelaniya, Colombo, Sri Lanka.
Arka DeDepartment of Hepatology, Postgraduate Institute of Medical Education and Research, Chandigarh 160012, India.
G P DhakalJigme Dorji Wangchuck National Referral Hospital (JDWNRH), Khesar Gyalpo University of Medical Sciences of Bhutan (KGUMSB), Thimphu, Bhutan.
Saeed HamidDepartment of Medicine, Aga Khan University, Karachi, Pakistan.
Kaushal MadanDepartment of Gastroenterology and Hepatology, Max Smart Super Specialty Hospital, Saket, New Delhi, 110017, India.
Manas K PanigrahiDepartment of Gastroenterology, All India Institute of Medical Sciences, Bhubaneswar, 751019, India.
P N RaoDepartment of Hepatology, Asian Institute of Gastroenterology, Hyderabad, 500082, India.
Sanjiv SaigalDepartment of Hepatology, Medanta Hospital, Gurugram, 122001, India.
Sanjaya K SatapathySandra Atlas Bass Center for Liver Diseases & Transplantation, Department of Medicine, North Shore University Hospital/Northwell Health, 400 Community Drive, Manhasset, NY 11030, USA.
ShalimarDepartment of Gastroenterology and Human Nutrition, All India Institute of Medical Sciences, New Delhi, 110016, India.
Ananta ShresthaLiver Foundation Nepal, Kathmandu, 44600, Nepal.
Akash ShuklaDepartment of Gastroenterology, Seth GSMC & KEM Hospital, Mumbai, 400022, India.
K C SudhamshuLiver Unit, Department of Medicine, Bir Hospital, Kathmandu, Nepal.
Hasitha WijewanthaDepartment of Gastroenterology and Hepatology, Provincial General Hospital, Badulla, Sri Lanka.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

There is an ongoing debate on the change of terminology of non-alcoholic fatty liver disease (NAFLD) to metabolic associated fatty liver disease (MAFLD). Experts from the Indian National Association for Study of the Liver (INASL) and the South Asian Association for Study of the Liver (SAASL) involved in diagnosing, managing, and preventing NAFLD met in March 2022 to deliberate if the name change from NAFLD to MAFLD is appropriate, as proposed by a group of experts who published a "consensus" statement in 2020. Proponents of name change to MAFLD opined that NAFLD does not reflect current knowledge, and the term MAFLD was suggested as a more appropriate overarching term. However, this "consensus" group which proposed the name change to MAFLD did not represent the views and opinions of gastroenterologists and hepatologists, as well as perceptions of patients across the globe, given the fact that change of nomenclature for any disease entity is bound to have multidimensional impact on all aspects of patient care. This statement is the culmination of the participants' combined efforts who presented recommendations on specific issues concerning the proposed name change. The recommendations were then circulated to all the core group members and updated based on a systematic literature search. Finally, all the members voted on them using the nominal voting technique as per the standard guidelines. The quality of evidence was adapted from the Grades of Recommendation, Assessment, Development and Evaluation system.

Indexed as

fatty livername changeSouth Asiastigmaterminology

Identifiers

PMID37250868
PMCPMC10213851

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.